Apellis Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	405.21	466.23	411.29	351.19	551.8	640.19
Short-Term Investments	0.99	1.55	4.85	4.35	6.51	61.04
Cash & Short-Term Investments	406.2	467.79	416.14	355.54	558.31	701.23
Cash Growth	12.11%	12.41%	17.04%	-36.32%	-20.38%	-20.10%
Accounts Receivable	445.11	369.16	271.72	224.5	29.17	80.1
Other Receivables	-	-	-	-	8.71	-
Receivables	445.11	369.16	271.72	224.5	37.88	80.1
Inventory	133.61	144.76	82.48	162.66	99.7	24
Prepaid Expenses	17.38	9.52	9.51	8.59	7.18	5.17
Restricted Cash	1.52	1.53	1.32	1.11	1.27	1.56
Other Current Assets	24.2	22.1	7.78	13.93	15.18	11.98
Total Current Assets	1,028	1,015	788.95	766.33	719.52	824.05
Property, Plant & Equipment	20.36	19.9	19.04	21.09	24.9	26.08
Long-Term Accounts Receivable	-	-	-	-	15	30
Other Long-Term Assets	34.15	40.51	77.06	1.31	0.8	1.64
Total Assets	1,083	1,075	885.05	788.73	760.22	881.77
Accounts Payable	49.05	56.8	38.57	37.52	37.34	16.91
Accrued Expenses	133.69	166.05	140.18	127.81	95.14	103.24
Current Portion of Long-Term Debt	93.74	93.66	-	-	-	-
Current Portion of Leases	6.96	7.09	6.75	6.44	5.63	4.12
Other Current Liabilities	-	-	-	75.83	29.5	7.58
Total Current Liabilities	283.45	323.6	185.51	247.59	167.61	131.85
Long-Term Debt	362.24	361.66	452.83	93.03	92.74	189.02
Long-Term Leases	12.81	11.95	10.2	11.45	14.35	17.08
Other Long-Term Liabilities	9.11	7.9	7.97	242.13	315.65	345.15
Total Liabilities	667.61	705.11	656.51	594.21	590.35	683.1
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	3,412	3,385	3,267	3,036	2,480	1,857
Retained Earnings	-2,994	-3,013	-3,035	-2,837	-2,309	-1,657
Comprehensive Income & Other	-2.41	-2.1	-3.31	-3.54	-0.88	-2.09
Total Common Equity	414.92	370.15	228.54	194.52	169.87	198.66
Shareholders' Equity	414.92	370.15	228.54	194.52	169.87	198.66
Total Liabilities & Equity	1,083	1,075	885.05	788.73	760.22	881.77
Total Debt	475.76	474.36	469.78	110.93	112.71	210.22
Net Cash (Debt)	-69.56	-6.57	-53.65	244.61	445.59	491.01
Net Cash Growth	-	-	-	-45.10%	-9.25%	-1.78%
Net Cash Per Share	-0.53	-0.05	-0.43	2.06	4.20	5.82
Filing Date Shares Outstanding	128.02	127.83	125.52	120.58	111.29	97.73
Total Common Shares Outstanding	127.92	126.62	124.5	119.56	110.77	97.52
Working Capital	744.57	691.24	603.45	518.74	551.91	692.2
Book Value Per Share	3.24	2.92	1.84	1.63	1.53	2.04
Tangible Book Value	414.92	370.15	228.54	194.52	169.87	198.66
Tangible Book Value Per Share	3.24	2.92	1.84	1.63	1.53	2.04

SEC Filings: 10-K · 10-Q